Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era-Reference-Cited by-同舟云学术

Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era

Published:2016-01-05 Issue:5 Volume:172 Page:724-734
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Nastoupil Loretta J.¹,Sinha Rajni²,Byrtek Michelle³,Ziemiecki Ryan⁴,Zhou Xiaolei⁴,Taylor Michael³,Friedberg Jonathan W.⁵,Link Brian K.⁶,Cerhan James R.⁷,Dawson Keith³,Flowers Christopher R.⁸

Affiliation:

1. The University of Texas MD Anderson Cancer Center; Houston TX USA

2. University Oncology & Hematology Associates; Chattanooga TN USA

3. Genentech/Roche; South San Francisco CA USA

4. Biostatistics; RTI Health Solutions; Research Triangle Park NC USA

5. James P. Wilmot Cancer Center; University of Rochester; Rochester NY USA

6. Holden Comprehensive Cancer Center; University of Iowa; Iowa City IA USA

7. Department of Health Sciences Research; Mayo Clinic; Rochester MN USA

8. Winship Cancer Institute; Emory University; Atlanta GA USA

Funder

Genentech Inc./F. Hoffmann-La Roche Ltd

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13895/fullpdf

Reference20 articles.

1. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial;Ardeshna;The Lancet,2003

2. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial;Ardeshna;The Lancet Oncoogy,2014

3. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma;Bachy;Haematologica,2013

4. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte;Brice;Journal of Clinical Oncology,1997

5. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group;D'Agostino;Statistics in Medicine,1998

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilization of Real-World Data to Facilitate Clinical Trials for Patients with Lymphoma;Pharmacoepidemiology;2024-08-06

2. Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States;Value in Health;2024-08

3. Clinical Characteristics and Prognosis of Patients with Follicular Lymphoma Grade 3A: A real-world study in a single centre;2024-06-12

4. Advancements in the Management of Follicular Lymphoma: A Comprehensive Review;Turkish Journal of Hematology;2024-05-30

5. Lenalidomide, rituximab (R ² ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma;Leukemia & Lymphoma;2024-03-08